DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITION

Yee-Shin Lin (Inventor)

Research output: Patent

Abstract

The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1). Therefore, the dengue vaccine without autoimmunity according to the present invention is able to avoid cross-reactions
Translated title of the contribution登革疫苗、包含該登革疫苗之醫藥組合物、核?酸序列、以及抗體組成物
Original languageEnglish
Patent number8771704
Publication statusPublished - 2012 Mar 22

Fingerprint

Dive into the research topics of 'DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITION'. Together they form a unique fingerprint.

Cite this